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Background: Beta- blocker therapy has been suggested to have neuroprotective prop-
erties in the setting of acute stroke; however, the evidence is weak and contradictory. 
We aimed to examine the effects of pre- admission therapy with beta- blockers (BB) on 
the mortality following spontaneous intracerebral hemorrhage (ICH).
Methods: Retrospective analysis of the Helsinki ICH Study database.
Results: A total of 1013 patients with ICH were included in the analysis. Patients 
taking BB were significantly older, had a higher premorbid mRS score, had more 
DNR orders, and more comorbidities as atrial fibrillation, hypertension, diabetes 
mellitus, ischemic heart disease, and heart failure. After adjustment for age, pre- 
existing comorbidities, and prior use of antithrombotic and antihypertensive medi-
cations, no differences in in- hospital mortality (OR 1.1, 95% CI 0.8- 1.7), 12- month 
mortality (OR 1.3, 95% CI 0.9- 1.9), and 3- month mortality (OR 1.2, 95% CI 0.8- 1.7) 
emerged.
Conclusion: Pre- admission use of BB was not associated with mortality after ICH.
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1  | INTRODUCTION
Acute stroke including intracerebral hemorrhage (ICH) has been shown 
to elicit massive activation of the sympathetic nervous system respon-
sible for complication as hypertensive derangement, cardiac changes, 
or immunodepression.1,2 Thus, anti- adrenergic medication has been 
studied for neuroprotective properties in this setting. Previous reports 
indicate that prestroke beta- blocker (BB) therapy in ischemic stroke 
may be associated with decreased stroke severity and overall mor-
tality.3,4 However, other reports contradict these findings.5 In ICH, 
BB- therapy has been proposed to reduce perihematomal edema, in-
fection rates, and mortality.6-8 However, a huge national registry could 
not verify positive effects of BB on short- term mortality after ICH.9 
Given the inconclusiveness of the previous studies, we aimed to test 
the  hypothesis that prestroke BB- therapy is associated with mortality 
after ICH.
2  | METHODS
This study was based on the Helsinki ICH Study database, a retro-
spective collection of all consecutive patients with ICH treated at the 
Helsinki University Central Hospital from January 2005 to March 2010, 
as published in detail previously.10 Briefly, the database is based on ret-
rospectively retrieved data from medical records. The Glasgow Coma 
Scale (GCS) was systematically registered for patients at the emergency 
department, and the National Institutes of Health Stroke Scale was re-
constructed from chart notes. Information on comorbidities and previ-
ous medications were retrieved from the province- wide hospital notes 
of all specialties and general practice referral notes. All scans were evalu-
ated by neuroradiologists at our hospital, and we included all subsequent 
scans after the ICH in our analysis. Lesion volumes were estimated with 
the ABC/2 method.11 We recorded the modified Rankin Scale (mRS) 
at discharge but did not have systematic follow- up visits, wherefore 
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functional outcome could not be evaluated after discharge. For this 
reason, we used mortality as our primary outcome with date of death 
retrieved from Statistics Finland in October 2011 for all residents of our 
province. The study has been approved by institutional authorities. As a 
routine observational quality registry with no patient contact, consent 
for registration was not required by Finnish legislation.
3  | STATISTICS
Due to non- normal distribution of all continuous variables, me-
dian with interquartile range is reported. Groups were compared 
with the Pearson chi- squared test with two- sided statistical sig-
nificance set at 0.05. Multivariable logistic regression models 
with the dependent variables in- hospital mortality, mortality at 
3 months, and mortality at 12 months were performed to test for 
possible impact of the prior BB- therapy after adjustment for fol-
lowing confounders: age, prior mRS>1, atrial fibrillation, hyper-
tension, diabetes mellitus, ischemic heart disease, heart failure, 
admission glycemia, prior anticoagulants, prior antiplatelets, and 
previous therapy with angiotensin converting enzyme inhibitors 
(ACEI), angiotensin receptors antagonists (ARB), and calcium 
blockers (CA). Analyses were performed on IBM SPSS 20 (IBM 
Corp, Armonk, NY).
Characteristic
BB- naive, n = 724 
(71.5%)
BB before ICH, 
n = 289 (28.5%) P
Male gender, n (%) 413 (57.0) 169 (58.5) .7
Age, years, mean (range, SD) 65.4 (22- 93, 13.7) 70.3 (31- 97, 12.3) <.001
Prior mRS>1 71 (9.8) 63 (21.8) <.001
Atrial fibrillation, n (%) 52 (7.3) 90 (31.3) <.001
Hypertension, n (%) 352 (48.6) 285 (98.6) <.001
Diabetes mellitus, n (%) 63 (8.7) 79 (27.3) <.001
Ischemic heart disease, n (%) 36 (5.0) 92 (31.9) <.001
Heart failure, n (%) 18 (2.5) 30 (10.5) <.001
Admission NIHSS, median (range, IQR) 11 (0- 40, 15) 12 (0- 40, 15) .14
Admission GCS, median (range, IQR) 14 (3- 15, 5) 14 (3- 15, 5) .79
ICH score, median (range, IQR) 1 (0- 6, 2) 1 (0- 5, 2) .23
Hemorrhage volume, median (range, 
IQR)
10.4 (0- 274, 22.6) 8.8 (0.1- 171, 25.7) .72
IVH, n (%) 297 (41.0) 115 (39.8) .7
Infratentorial localization, n (%) 102 (14.1) 40 (13.8) 1.0
Basal ganglia localization, n (%) 317 (43.8) 116 (40.1) .3
Hemorrhage growth 33% or >6 mL, n 
(%)
101 (28.7) 44 (32.4) .4
Admission blood glucose, median 
(range, IQR)
7.9 (3.5- 54.8, 3) 8.6 (2.7- 28.9, 3.5) .009
Admission systolic BP, median (range, 
IQR)
169 (70- 280, 44) 173 (34- 191, 25) .35
Admission diastolic BP, median (range, 
IQR)
92 (34- 191, 26) 88 (35- 162, 25) .02
Prior OAC, n (%) 60 (8.3) 83 (28.7) <.001
Prior antiplatelet, n (%) 143 (19.8) 122 (42.2) <.001
Prior ACEI, n (%) 63 (8.7) 91 (31.5) <.001
Prior ARB, n (%) 59 (8.1) 57 (19.7) <.001
Prior CA, n (%) 61 (8.4) 63 (21.8) <.001
In- hospital mortality, n (%) 161 (22.2) 83 (28.7) .03
Mortality at 3 mo, n (%) 206 (29.2) 111 (39.8) .002
Mortality at 12 mo, (%) 228 (32.3) 130 (46.6) <.001
N, frequency; SD, standard deviation; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, 
National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; 
IVH, intraventricular hemorrhage; BP, blood pressure; OAC, oral anticoagulants; ACEI, angiotensin con-
verting enzyme inhibitors; ARB, angiotensin receptors antagonists; CA, calcium blockers.
TABLE  1 Characteristics and mortality 
of BB- naïve patients vs those treated with 
BBs before ICH onset
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4  | RESULTS
In total, 1013 patients with ICH were extracted from the database 
and included in the analysis. Out of 1013 patients, 289 (28.5%) were 
taking BB at the time of index ICH and 724 (71.5%) were BB- naïve. 
Compared to patients not taking BB prior to ICH, those taking BB were 
significantly older (70.3 vs 65.4 years, P < .001), had a higher premor-
bid modified Rankin Score (mRS>1: 21.8% vs 9.8%, P < .001), had 
more comorbidities such as atrial fibrillation (31.3% vs 7.3%, P < .001), 
hypertension (98.6% vs 48.6%, P < .001), diabetes mellitus (27.3% vs 
8.7%, P < .001), ischemic heart disease (31.9% vs 5%, P < .001), and 
heart failure (10.5% vs 2.5%, P < .001). Furthermore, patients on BB 
had more often prior oral anticoagulant treatment (28.7% vs 8.3%, 
P < .001), more often antiplatelet drugs (42.2% vs 19.8%, P < .001), 
and more often other antihypertensive drugs (ACEI: 31.5% vs 8.7%, 
ARB: 19.7% vs 8.1%, CA: 21.8% vs 8.4%, all P < .001), see also 
Table 1. Patients on BB also had more often do- not- resuscitate orders 
(n = 121, 41.9% vs n = 237, 32.7%; P = .007). The hemorrhage char-
acteristics as well as the clinical status on admission were comparable 
between the groups (hemorrhage volume 8.8 mL vs 10.4 mL, P = .72; 
admission GCS 14 vs 14, P = .79), see also Table 1.
In the entire study population, in- hospital mortality was 24.1%, 
3- month mortality 31.1%, and 12- month mortality 35.3%. Mortality at 
every time point was higher in the group of patients on pre- ICH BB- 
therapy as compared to BB- naïve patients. In BB- pretreated patients 
compared to BB- naïve patients, the in- hospital mortality, 3- months 
mortality, and 12- month mortality were 28.7%, 39.8%, and 46.6% as 
compared to 22.2%, 29.2%, and 32.3% (P = .03, P = .002, and<.001), 
respectively. After multivariable adjustment, no effects of prior BB- 
therapy on in- hospital (adjusted OR 1.1, 95% CI 0.8- 1.7), 3- month 
mortality (adjusted OR 1.2, 95% CI 0.8- 1.7), and 12- month mortality 
(adjusted OR 1.3, 95% CI 0.9- 1.9) could be observed.
5  | DISCUSSION
In animal models, prestroke beta- blockade leads to decreased 
stroke lesion volumes, lesser infections, better functional outcome, 
and lower mortality.12,13 As increased heart rate as a surrogate for 
sympathetic activation has been consistently found to be associated 
with poor outcome and higher mortality in all stroke types,14-16 sym-
patholytic therapies may appear reasonable. However, the evidence 
from human studies is not straight forward. Confirmatory as well as 
negative studies exist on the beneficial effects of the prestroke BB- 
therapy in acute ischemic stroke.3-5,9 A study by Laowattana found 
decreased ischemic stroke severity on admission in those taking 
BB- therapy.4 On the other hand, later studies could not find any as-
sociation between prestroke BB- therapy and stroke severity or out-
come.5,17 In our previous study, we found no effects of pretreatment 
BB on stroke severity, mortality and functional outcome; however, 
patients newly started with BB within the first 3 days after onset 
had lower infections rates and lower mortality.18 Interestingly, there 
are some positive studies of protective effects of beta- blockers in 
subarachnoidal hemorrhage (SAH) and traumatic brain injury (TBI), 
both pathologies inducing marked sympathetic hyperactivity. Study 
by Chalouhi suggested that pre- admission therapy with BBs may 
reduce the incidence of vasospasms after SAH.19 Another study 
in SAH patients suggested improved discharge characteristics and 
lower mortality in those treated with BB.20 For TBI, recent stud-
ies and meta- analyses consistently suggest mortality and outcome 
benefits with beta- blockade.21-23 Data in patients with spontaneous 
ICH are scarce and include both positive and negative signals.6-9 A 
study by Kalita suggested reduction in mortality, SIRS, and pneumo-
nia with the in- hospital use of atenolol in patients with ICH.6 Other 
studies found no association between BB pretreatment and out-
come in ICH.7,9 In line with the later studies, we found no effects of 
pre- admission BB on mortality after ICH, thus, contributing to the 
negative body of evidence within this topic. We hypothesize that 
the effects of random prestroke BB exposure and post- admission 
beta- blockade on stroke outcome may be different. This is also the 
point where most of the studies diverge.
Limitations of our study have to be acknowledged. BB in this cohort 
were principally uncontrolled, highly heterogeneous in substances and 
dosages as well as in indications for administration. The main source 
of possible bias is, therefore, the confounding by indication. Despite 
having adjusted the analysis for the between- group imbalances, one 
cannot completely rule out hidden effects. Further drawback is the 
retrospective, non- randomized character of the analysis. The strength 
of our study, however, is the data from a large homogeneous mono-
centric registry of consecutive ICH patients with rigorously collected 
clinical and radiological variables and outcomes.
6  | CONCLUSION
In the recent large monocentric non- randomized comparison, we 
could not find any association of pretreatment BB with mortality after 
ICH.
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